Danielle Marie Brander, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box 3841 DUMC, Durham, NC 27710
Phone (919) 684-8111
Email address danielle.brander@duke.edu

Education and Training

  • Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
  • M.D., Duke University School of Medicine, 2007

Publications

Burris, HA, Flinn, IW, Patel, MR, Fenske, TS, Deng, C, Brander, DM, Gutierrez, M, Essell, JH, Kuhn, JG, Miskin, HP, Sportelli, P, Weiss, MS, Vakkalanka, S, Savona, MR, and O'Connor, OA. "Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study." The Lancet. Oncology 19, no. 4 (April 2018): 486-496.

PMID
29475723
Full Text

Wierda, WG, Byrd, JC, Abramson, JS, Bhat, S, Bociek, G, Brander, D, Brown, J, Chanan-Khan, A, Coutre, SE, Davis, RS, Fletcher, CD, Hill, B, Kahl, BS, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Lancet, J, Ma, S, Malek, S, Mosse, C, Shadman, M, Siddiqi, T, Stephens, D, Wagner, N, and Zelenetz, AD. "Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology." JNCCN Journal of the National Comprehensive Cancer Network 15, no. 11 (November 1, 2017): 1414-1427. (Review)

Full Text

Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, A-L, Claxton, DF, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ, and Nabhan, C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of oncology : official journal of the European Society for Medical Oncology 28, no. 5 (May 2017): 1050-1056.

PMID
28453705
Full Text

Seymour, JF, Ma, S, Brander, DM, Choi, MY, Barrientos, J, Davids, MS, Anderson, MA, Beaven, AW, Rosen, ST, Tam, CS, Prine, B, Agarwal, SK, Munasinghe, W, Zhu, M, Lash, LL, Desai, M, Cerri, E, Verdugo, M, Kim, SY, Humerickhouse, RA, Gordon, GB, Kipps, TJ, and Roberts, AW. "Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study." The Lancet. Oncology 18, no. 2 (February 2017): 230-240.

PMID
28089635
Full Text

Brander, DM. "Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?." British journal of haematology 176, no. 3 (February 2017): 337-340.

PMID
27984636
Full Text

Strati, P, Lanasa, M, Call, TG, Leis, JF, Brander, DM, LaPlant, BR, Pettinger, AM, Ding, W, Parikh, SA, Hanson, CA, Chanan-Khan, AA, Bowen, DA, Conte, M, Kay, NE, and Shanafelt, TD. "Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial." The Lancet. Haematology 3, no. 9 (September 2016): e407-e414.

PMID
27570087
Full Text

Friedman, DR, Lanasa, MC, Davis, PH, Allgood, SD, Matta, KM, Brander, DM, Chen, Y, Davis, ED, Volkheimer, AD, Moore, JO, Gockerman, JP, Sportelli, P, and Weinberg, JB. "Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies." Leuk Lymphoma 55, no. 5 (May 2014): 1067-1075.

PMID
23863122
Full Text

Brander, D, Rizzieri, D, Gockerman, J, Diehl, L, Shea, TC, Decastro, C, Moore, JO, and Beaven, A. "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma." Leukemia & lymphoma 54, no. 12 (December 2013): 2627-2630.

PMID
23488610
Full Text

Brander, DM, and Beaven, AW. "Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib." Patient preference and adherence 6 (January 2012): 239-251.

PMID
22536060
Full Text

Bean, GR, Bryson, AD, Pilie, PG, Goldenberg, V, Baker, JC, Ibarra, C, Brander, DMU, Paisie, C, Case, NR, Gauthier, M, Reynolds, PA, Dietze, E, Ostrander, J, Scott, V, Wilke, LG, Yee, L, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Tlsty, TD, and Seewaldt, VL. "Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF." Clinical cancer research : an official journal of the American Association for Cancer Research 13, no. 22 Pt 1 (November 2007): 6834-6841.

PMID
18006786
Full Text